stockrowKiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.
- Revenue
- +58.1%
- EPS
- +142.2%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
Follow KNSA
Alert me
Kiniksa Pharmaceuticals International, plc (KNSA) Total debt
Kiniksa Pharmaceuticals International, plc's total debt at the end of fiscal 2022 was $5.9M, unchanged from fiscal 2021. At the end of the quarter to 30 September 2023 it was $13.0M. Kiniksa Pharmaceuticals International, plc ranks 50th of 84 Drug Manufacturers Specialty & Generic companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $5.9M | (2.17%) |
| FY2021 | $6.1M | (13.39%) |
| FY2020 | $7.0M | 163.39% |
| FY2019 | $2.7M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $13.0M | (4.12%) |
| Jun 2023 | $13.5M | 140.80% |
| Mar 2023 | $5.6M | (5.14%) |
| Dec 2022 | $5.9M | (11.78%) |
| 12 more quarters | Free account |
Total debt against peers
| Company | Total debt |
|---|---|
| ELAN Elanco Animal Health Incorporated compare | $3.9B |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $3.2B |
| ALKS Alkermes plc compare | $1.5B |
| HIMS Hims & Hers Health, Inc. compare | $1.4B |
| RDY Dr. Reddy's Laboratories Ltd compare | $753.0M |
| LNTH Lantheus Holdings, Inc. compare | $571.7M |
| SUPN Indivior Pharmaceuticals Inc. compare | $488.0M |
| LQDA Liquidia Corporation compare | $176.1M |
| KNSA Kiniksa Pharmaceuticals International, plc | $13.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on KNSA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement